 CAMBRIDGE, Mass. and LONDON, June 04, 2021 GLOBE NEWSWIRE -- Centessa Pharmaceuticals plc Centessa, a clinical-stage company employing its innovative asset-centric business model to discover, develop and ultimately deliver impactful medicines to patients, announced today that, in connection with its previously announced initial public offering of 16,500,000 American Depositary Shares ADSs, the underwriters have fully exercised their option to purchase an additional 2,475,000 ADSs at the initial public offering price of 20.00 per ADS, less underwriting discounts and commissions. The closing of the initial public offering occurred on June 2, 2021 and the issuance and sale of the additional ADSs closed today. The gross proceeds to Centessa from its initial public offering, before deducting underwriting discounts, commissions and other estimated offering expenses, totaled an aggregate of 379.5 million. 